{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:53:14Z","timestamp":1790977994621,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although hypertension is a major contributor to cardiovascular complications, real-world blood pressure (BP) control in primary care and the role of hypertension specialists remain incompletely characterized. We evaluated BP control and associated factors using the Japan Medical Association Database of Clinical Medicine (J-DOME), a nationwide primary care registry. This cross-sectional study included patients with hypertension registered in 2024, categorized by treatment by specialists certified by the Japanese Society of Hypertension. Multivariable logistic regression identified factors associated with achieving office BP\u2009&lt;\u2009130\/80\u2009mmHg. Among 2663 patients (43.6% women; mean age, 71.4 years), 545 were treated by hypertension specialists. Mean BP was 134.4\/74.8\u2009mmHg, and the mean number of antihypertensive drugs was 1.6. Systolic BP was similar between specialist- and non-specialist-treated patients (135.1\n                    <jats:italic>vs<\/jats:italic>\n                    . 134.2\u2009mmHg;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.28), whereas diastolic BP (76.1\n                    <jats:italic>vs<\/jats:italic>\n                    . 74.5\u2009mmHg;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0060) and the number of drugs (1.9\n                    <jats:italic>vs<\/jats:italic>\n                    . 1.6;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001) were higher in the specialist-treated group. Target BP achievement rate was lower in the specialist-treated group (30.8%\n                    <jats:italic>vs<\/jats:italic>\n                    . 37.3%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0058), however, this difference was not observed among patients aged &lt;75 years (33.2% vs. 35.4%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.55). The multivariable-adjusted model revealed that diabetes mellitus (odds ratio [OR], 1.32; 95% confidence interval [CI], 1.08\u20131.61) and a higher number of drugs (OR per additional drug, 1.12; 95% CI, 1.04\u20131.22) were associated with higher target achievement, whereas overweight (OR, 0.70; 95% CI, 0.58\u20130.85), obesity (OR, 0.57; 95% CI, 0.42\u20130.77), and specialist treatment (OR, 0.77; 95% CI, 0.61\u20130.96) were associated with lower achievement. Office BP control remains suboptimal in Japanese primary care. Lower achievement among specialist-treated patients despite more drugs may reflect the concentration of difficult-to-control hypertension in specialist care. Continued efforts to improve hypertension management, particularly in patients with obesity, are warranted.\n                  <\/jats:p>","DOI":"10.1038\/s41440-026-02833-z","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:35:41Z","timestamp":1790930141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of hypertension specialist treatment with blood pressure control in Japanese primary care: The J-DOME study"],"prefix":"10.1038","author":[{"given":"Daigoro","family":"Hirohama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narumi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuguru","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuomi","family":"Kario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiko","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Nozato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Ushigome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Asayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the J-DOME Research Analysis Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"10022","key":"2833_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957\u201367.","journal-title":"Lancet"},{"issue":"9349","key":"2833_CR2","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903\u201313.","journal-title":"Lancet"},{"issue":"22","key":"2833_CR3","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr.","year":"2015","unstructured":"Wright JT Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103\u201316.","journal-title":"N Engl J Med"},{"issue":"14","key":"2833_CR4","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021;385(14):1268\u201379.","journal-title":"N Engl J Med"},{"issue":"12","key":"2833_CR5","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2412006","volume":"392","author":"Y Bi","year":"2025","unstructured":"Bi Y, Li M, Liu Y, Li T, Lu J, Duan P, et al. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N Engl J Med. 2025;392(12):1155\u201367.","journal-title":"N Engl J Med"},{"issue":"10449","key":"2833_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","volume":"404","author":"J Liu","year":"2024","unstructured":"Liu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024;404(10449):245\u201355.","journal-title":"Lancet"},{"issue":"18","key":"2833_CR7","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"DW Jones","year":"2025","unstructured":"Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;86(18):1567\u2013678.","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"2833_CR8","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912\u20134018.","journal-title":"Eur Heart J"},{"issue":"1","key":"2833_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41440-025-02462-y","volume":"49","author":"Y Ohya","year":"2026","unstructured":"Ohya Y, Arakawa K, Arata N, Arima S, Arima H, Asayama K, et al. The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025). Hypertens Res. 2026;49(1):9\u2013235.","journal-title":"Hypertens Res"},{"key":"2833_CR10","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2021","unstructured":"NCD Risk Factor Collaboration (NCD-RisC)Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957\u201380.","journal-title":"Lancet"},{"issue":"6","key":"2833_CR11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134(6):441\u201350.","journal-title":"Circulation"},{"key":"2833_CR12","doi-asserted-by":"crossref","unstructured":"Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet. 2019;394(10199):639\u201351.","DOI":"10.1016\/S0140-6736(19)31145-6"},{"issue":"7","key":"2833_CR13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1080\/10641963.2020.1764017","volume":"42","author":"S Fujishima","year":"2020","unstructured":"Fujishima S, Kodama S, Tsuchihashi T. Achievement rate of blood pressure <140\/90 mmHg and <130\/80 mmHg in subjects with hypertension; findings from a Japanese health checkup in 2017. Clin Exp Hypertens. 2020;42(7):648\u201355.","journal-title":"Clin Exp Hypertens"},{"issue":"11","key":"2833_CR14","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1038\/s41440-023-01362-3","volume":"46","author":"A Sakima","year":"2023","unstructured":"Sakima A, Yamazato M, Kohagura K, Ishida A, Matayoshi T, Tana T, et al. Achievement rate of target blood pressure in patients with hypertension treated by hypertension specialists and non-specialists in a real-world setting. Hypertens Res. 2023;46(11):2460\u20139.","journal-title":"Hypertens Res"},{"issue":"4","key":"2833_CR15","first-page":"1307","volume":"8","author":"M Noda","year":"2025","unstructured":"Noda M, Ueki K, Goto A, Node K, Rakugi H, Eguchi N. Regional Differences and Similarities in Diabetes Care in Japan: Insights from the J-DOME Registry. JMA J. 2025;8(4):1307\u201314.","journal-title":"JMA J"},{"issue":"11","key":"2833_CR16","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1038\/s41440-023-01366-z","volume":"46","author":"K Kobayashi","year":"2023","unstructured":"Kobayashi K, Chin K, Hatori N, Furuki T, Sakai H, Miyakawa M, et al. Cross-sectional survey of hypertension management in clinical practice in Japan: the Kanagawa Hypertension Study 2021 conducted in collaboration with Japan Medical Association Database of Clinical Medicine. Hypertens Res. 2023;46(11):2447\u201359.","journal-title":"Hypertens Res"},{"key":"2833_CR17","first-page":"1","volume":"894","author":"Obesity: preventing and managing the global epidemic","year":"2000","unstructured":"Obesity: preventing and managing the global epidemicReport of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:1\u2013253.","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"3","key":"2833_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw. 2011;45(3):1\u201367.","journal-title":"J Stat Softw"},{"issue":"11","key":"2833_CR19","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1038\/s41440-025-02355-0","volume":"48","author":"K Kario","year":"2025","unstructured":"Kario K. Achievement rate of blood pressure control <130\/80\u2009mmHg as the core metric of implementation hypertension, based on the new JSH2025 and AHA\/ACC2025 guidelines. Hypertens Res. 2025;48(11):2784\u20138.","journal-title":"Hypertens Res"},{"issue":"9","key":"2833_CR20","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42(9):1235\u2013481.","journal-title":"Hypertens Res"},{"issue":"6","key":"2833_CR21","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1161\/CIRCRESAHA.118.314487","volume":"124","author":"D Sun","year":"2019","unstructured":"Sun D, Zhou T, Heianza Y, Li X, Fan M, Fonseca VA, et al. Type 2 Diabetes and Hypertension. Circ Res. 2019;124(6):930\u20137.","journal-title":"Circ Res"},{"issue":"5","key":"2833_CR22","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1161\/HYPERTENSIONAHA.121.17981","volume":"78","author":"G Jia","year":"2021","unstructured":"Jia G, Sowers JR. Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease. Hypertension. 2021;78(5):1197\u2013205.","journal-title":"Hypertension"},{"issue":"6","key":"2833_CR23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","volume":"116","author":"JE Hall","year":"2015","unstructured":"Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991\u20131006.","journal-title":"Circ Res"},{"issue":"12","key":"2833_CR24","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41440-019-0332-5","volume":"42","author":"D Hirohama","year":"2019","unstructured":"Hirohama D, Fujita T. Evaluation of the pathophysiological mechanisms of salt-sensitive hypertension. Hypertens Res. 2019;42(12):1848\u201357.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02833-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02833-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02833-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:02:46Z","timestamp":1790974966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02833-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":24,"alternative-id":["2833"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02833-z","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"26 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS received honoraria from AstraZeneca, Daiichi Sankyo Co., Ltd., Bayer, Boehringer Ingelheim, and Kyowa Kirin Co., Ltd., and research funding from AstraZeneca. TH received honoraria from Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Boehringer Ingelheim, and AstraZeneca. KKa received honoraria from Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., and CureApp, Inc., and research funding from A&D Company, Limited, Omron Healthcare Co., Ltd., and Fukuda Denshi Co., Ltd. TK received honoraria from Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., and CureApp, Inc. KKo received lecture fees from Otsuka Pharmaceutical Co., Ltd., and Novartis Pharma K.K. KA is an academic consultant for Omron Healthcare Co., Ltd., and A&D Company, Limited. NE, DH, AN, MN, YN, KSa, KSh, and EU declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}